ClinicalTrials.gg
CompletedNCT01250730Updated Nov 29, 2011Results posted

A Study In Japanese Healthy Male Volunteers To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-02341066

A Phase 1 interventional study of PF-02341066 and PF-02341066 in Healthy, sponsored by Pfizer. Completed at 1 site in Japan. Open to male participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-11-29.

Sponsored by Pfizer · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Ages
20 Years to 55 Years
Sex
Male
01

Study summary

The purpose of this study is to investigate the pharmacokinetics of single doses of PF-02341066 (150, 250, and 400 mg) in the fasted condition in Japanese healthy male volunteers.

Read the detailed description

The purpose of this study is to investigate the pharmacokinetics of single doses of PF-02341066 (150, 250, and 400 mg) in the fasted condition in Japanese healthy male volunteers.

02

Conditions studied

  • Healthy

Keywords

  • PK profile in Japanese healthy male volunteers
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects, inclusive (Healthy is defined as no abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead and clinical laboratory tests).
  • (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg

Exclusion criteria

Exclusion Criteria:

  • Subjects who are smoking,
  • Subjects with evidence of disease,
  • Subjects with conditions affecting absorption,
  • Subjects with treatment with other drug within 30 days,
  • Subjects with history of regular alcohol consumption,
  • Subjects with use of prescription, nonprescription drugs and dietary supplement within 28 days,
  • Subjects with blood donation of approximately 400 mL within 3 months or 200 mL within 1 month prior to dosing
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    1.0

    This study will consist of three cohorts: PF-02341066 150 mg treatment group (n = 6), PF-02341066 250 mg treatment group (n = 6) and PF-02341066 400 mg treatment group (n = 6).

    Drug: PF-02341066

Interventions

  • Cohort 1: a 150 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 1 x 100 mg IRT.

  • Cohort 2: a 250 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 2 x 100 mg IRTs.

  • Cohort 3: a 400 mg single dose of PF-02341066 administered as 4 x 100 mg IRTs.

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time [AUC(0-inf)] of Crizotinib

    AUC(0-inf) of crizotinib is estimated from the crizotinib concentration. It is obtained from AUClast plus (Clast/kel). AUClast = area under the plasma concentration-time curve from zero time until the last measurable concentration. Clast = the last quantifiable concentration. Kel = terminal phase elimination rate constant.

    Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose

  2. Area Under the Plasma Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Crizotinib

    AUClast of crizotinib is estimated from the crizotinib concentration. It is obtained from Linear/Log trapezoidal method.

    Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose

  3. Maximum Plasma Concentration (Cmax) of Crizotinib

    Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose

  4. Time to Cmax (Tmax) of Crizotinib

    Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose

  5. Terminal Elimination Half-life (t1/2) of Crizotinib

    t1/2 of crizotinib is the time measured for the plasma concentration to decrease by one half. It is obtained from a Loge(2)/kel. Kel = terminal phase elimination rate constant

    Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose

  6. Apparent Oral Clearance (CL/F) of Crizotinib

    CL/F of crizotinib is obtained from a Dose per AUCinf.

    Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose

  7. Apparent Volume of Distribution (Vz/F) of Crizotinib

    Vz/F of crizotinib is obtained from a Dose / (AUCinf \*kel). Kel = terminal phase elimination rate constant

    Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose

  8. Dose Normalized AUC(0-inf) of Crizotinib

    Dose normalized (to 150 mg dose) AUC(0-inf) is obtained from AUC(0-inf) / (Dose/150).

    Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose

  9. Dose Normalized AUClast of Crizotinib

    Dose normalized (to 150 mg dose) AUClast is obtained from AUClast / (Dose/150).

    Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose

  10. Dose Normalized Cmax of Crizotinib

    Dose normalized (to 150 mg dose) Cmax is obtained from Cmax / (Dose/150).

    Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose

  11. Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time (AUC0-inf) of Plasma Active Metabolite (PF-06260182)

    AUC(0-inf) of PF-06260182 is estimated from the PF-06260182 concentration. It is obtained from AUClast plus (Clast/kel). AUClast = area under the plasma concentration-time curve from zero time until the last measurable concentration. Clast = the last quantifiable concentration. Kel = terminal phase elimination rate constant.

    Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose

  12. Area Under the Plasma Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Plasma Active Metabolite (PF-06260182)

    AUClast of crizotinib is estimated from the crizotinib concentration. It is obtained from Linear/Log trapezoidal method.

    Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose

  13. Maximum Plasma Concentration (Cmax) of Plasma Active Metabolite (PF-06260182)

    Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose

  14. Time to Cmax (Tmax) of Plasma Active Metabolite (PF-06260182)

    Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose

  15. Metabolite to Parent Ratio AUC(0-inf)

    The metabolic ratio (MR) is calculated by first converting the AUC(0-inf) for both crizotinib and metabolite (PF-06260182) from mass units to molar units.

    Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose

  16. Metabolite to Parent Ratio AUClast

    The metabolic ratio (MR) is calculated by first converting the AUClast for both crizotinib and metabolite (PF-06260182) from mass units to molar units.

    Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose

  17. Metabolite to Parent Ratio Cmax

    The metabolic ratio (MR) is calculated by first converting the Cmax for both crizotinib and metabolite (PF-06260182) from mass units to molar units.

    Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose

07

Results

Posted Nov 29, 2011

Participant flow

Participant flow — Overall Study
MilestoneCrizotinib 150 mgCrizotinib 250 mgCrizotinib 400 mg
Started666
Completed666
Not completed000

Outcome measures

PrimaryArea Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time [AUC(0-inf)] of Crizotinib

AUC(0-inf) of crizotinib is estimated from the crizotinib concentration. It is obtained from AUClast plus (Clast/kel). AUClast = area under the plasma concentration-time curve from zero time until the last measurable concentration. Clast = the last quantifiable concentration. Kel = terminal phase elimination rate constant.

Time frame:
0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time [AUC(0-inf)] of Crizotinib
ng*hr/mLCrizotinib 150 mgCrizotinib 250 mgCrizotinib 400 mg
Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time [AUC(0-inf)] of Crizotinib1423 ± 471.523806 ± 1313.26569 ± 2098.3
PrimaryArea Under the Plasma Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Crizotinib

AUClast of crizotinib is estimated from the crizotinib concentration. It is obtained from Linear/Log trapezoidal method.

Time frame:
0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Crizotinib
ng*hr/mLCrizotinib 150 mgCrizotinib 250 mgCrizotinib 400 mg
Area Under the Plasma Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Crizotinib1339 ± 472.663732 ± 1312.46386 ± 2084.7
PrimaryMaximum Plasma Concentration (Cmax) of Crizotinib
Time frame:
0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration (Cmax) of Crizotinib
ng/mLCrizotinib 150 mgCrizotinib 250 mgCrizotinib 400 mg
Maximum Plasma Concentration (Cmax) of Crizotinib70.54 ± 25.570155.6 ± 50.694235.8 ± 60.988
PrimaryTime to Cmax (Tmax) of Crizotinib
Time frame:
0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Reported as:
Median · ng/mL
Time to Cmax (Tmax) of Crizotinib
ng/mLCrizotinib 150 mgCrizotinib 250 mgCrizotinib 400 mg
Time to Cmax (Tmax) of Crizotinib5.00 (5.00 to 6.00)5.00 (4.00 to 6.00)5.00 (5.00 to 6.00)
PrimaryTerminal Elimination Half-life (t1/2) of Crizotinib

t1/2 of crizotinib is the time measured for the plasma concentration to decrease by one half. It is obtained from a Loge(2)/kel. Kel = terminal phase elimination rate constant

Time frame:
0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Reported as:
Mean · hours
Terminal Elimination Half-life (t1/2) of Crizotinib
hoursCrizotinib 150 mgCrizotinib 250 mgCrizotinib 400 mg
Terminal Elimination Half-life (t1/2) of Crizotinib41.08 ± 6.768329.90 ± 3.994529.13 ± 3.5753
PrimaryApparent Oral Clearance (CL/F) of Crizotinib

CL/F of crizotinib is obtained from a Dose per AUCinf.

Time frame:
0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Reported as:
Geometric mean · liter per hour
Apparent Oral Clearance (CL/F) of Crizotinib
liter per hourCrizotinib 150 mgCrizotinib 250 mgCrizotinib 400 mg
Apparent Oral Clearance (CL/F) of Crizotinib105.4 ± 33.92665.70 ± 30.50060.87 ± 16.936
PrimaryApparent Volume of Distribution (Vz/F) of Crizotinib

Vz/F of crizotinib is obtained from a Dose / (AUCinf \*kel). Kel = terminal phase elimination rate constant

Time frame:
0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Reported as:
Geometric mean · Liter
Apparent Volume of Distribution (Vz/F) of Crizotinib
LiterCrizotinib 150 mgCrizotinib 250 mgCrizotinib 400 mg
Apparent Volume of Distribution (Vz/F) of Crizotinib6170 ± 2843.72811 ± 1765.02545 ± 958.43
PrimaryDose Normalized AUC(0-inf) of Crizotinib

Dose normalized (to 150 mg dose) AUC(0-inf) is obtained from AUC(0-inf) / (Dose/150).

Time frame:
0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Dose Normalized AUC(0-inf) of Crizotinib
ng*hr/mLCrizotinib 150 mgCrizotinib 250 mgCrizotinib 400 mg
Dose Normalized AUC(0-inf) of Crizotinib1423 ± 471.522284 ± 787.922463 ± 786.84
PrimaryDose Normalized AUClast of Crizotinib

Dose normalized (to 150 mg dose) AUClast is obtained from AUClast / (Dose/150).

Time frame:
0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Dose Normalized AUClast of Crizotinib
ng*hr/mLCrizotinib 150 mgCrizotinib 250 mgCrizotinib 400 mg
Dose Normalized AUClast of Crizotinib1339 ± 472.662239 ± 787.452395 ± 781.75
PrimaryDose Normalized Cmax of Crizotinib

Dose normalized (to 150 mg dose) Cmax is obtained from Cmax / (Dose/150).

Time frame:
0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Reported as:
Geometric mean · ng/mL
Dose Normalized Cmax of Crizotinib
ng/mLCrizotinib 150 mgCrizotinib 250 mgCrizotinib 400 mg
Dose Normalized Cmax of Crizotinib70.54 ± 25.57093.36 ± 30.41688.41 ± 22.870
PrimaryArea Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time (AUC0-inf) of Plasma Active Metabolite (PF-06260182)

AUC(0-inf) of PF-06260182 is estimated from the PF-06260182 concentration. It is obtained from AUClast plus (Clast/kel). AUClast = area under the plasma concentration-time curve from zero time until the last measurable concentration. Clast = the last quantifiable concentration. Kel = terminal phase elimination rate constant.

Time frame:
0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time (AUC0-inf) of Plasma Active Metabolite (PF-06260182)
ng*hr/mLCrizotinib 150 mgCrizotinib 250 mgCrizotinib 400 mg
Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time (AUC0-inf) of Plasma Active Metabolite (PF-06260182)180.8 ± 99.369535.8 ± 274.231046 ± 549.90
PrimaryArea Under the Plasma Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Plasma Active Metabolite (PF-06260182)

AUClast of crizotinib is estimated from the crizotinib concentration. It is obtained from Linear/Log trapezoidal method.

Time frame:
0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Plasma Active Metabolite (PF-06260182)
ng*hr/mLCrizotinib 150 mgCrizotinib 250 mgCrizotinib 400 mg
Area Under the Plasma Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Plasma Active Metabolite (PF-06260182)188.1 ± 81.706527.2 ± 273.681034 ± 547.34
PrimaryMaximum Plasma Concentration (Cmax) of Plasma Active Metabolite (PF-06260182)
Time frame:
0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration (Cmax) of Plasma Active Metabolite (PF-06260182)
ng/mLCrizotinib 150 mgCrizotinib 250 mgCrizotinib 400 mg
Maximum Plasma Concentration (Cmax) of Plasma Active Metabolite (PF-06260182)17.24 ± 6.237137.63 ± 18.37254.94 ± 14.633
PrimaryTime to Cmax (Tmax) of Plasma Active Metabolite (PF-06260182)
Time frame:
0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Reported as:
Median · ng/mL
Time to Cmax (Tmax) of Plasma Active Metabolite (PF-06260182)
ng/mLCrizotinib 150 mgCrizotinib 250 mgCrizotinib 400 mg
Time to Cmax (Tmax) of Plasma Active Metabolite (PF-06260182)5.00 (4.00 to 6.00)5.00 (4.00 to 6.00)6.00 (5.00 to 8.00)
PrimaryMetabolite to Parent Ratio AUC(0-inf)

The metabolic ratio (MR) is calculated by first converting the AUC(0-inf) for both crizotinib and metabolite (PF-06260182) from mass units to molar units.

Time frame:
0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Reported as:
Geometric mean · ratio
Metabolite to Parent Ratio AUC(0-inf)
ratioCrizotinib 150 mgCrizotinib 250 mgCrizotinib 400 mg
Metabolite to Parent Ratio AUC(0-inf)0.1261 ± 0.02000.1365 ± 0.02720.1544 ± 0.0343
PrimaryMetabolite to Parent Ratio AUClast

The metabolic ratio (MR) is calculated by first converting the AUClast for both crizotinib and metabolite (PF-06260182) from mass units to molar units.

Time frame:
0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Reported as:
Geometric mean · ratio
Metabolite to Parent Ratio AUClast
ratioCrizotinib 150 mgCrizotinib 250 mgCrizotinib 400 mg
Metabolite to Parent Ratio AUClast0.1362 ± 0.02620.1370 ± 0.02720.1571 ± 0.0347
PrimaryMetabolite to Parent Ratio Cmax

The metabolic ratio (MR) is calculated by first converting the Cmax for both crizotinib and metabolite (PF-06260182) from mass units to molar units.

Time frame:
0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Reported as:
Geometric mean · ratio
Metabolite to Parent Ratio Cmax
ratioCrizotinib 150 mgCrizotinib 250 mgCrizotinib 400 mg
Metabolite to Parent Ratio Cmax0.2371 ± 0.08330.2346 ± 0.04410.2260 ± 0.0429

Adverse events

Collected over For serious adverse event, up to 28 days after the last administration of the study drugs. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Crizotinib 150 mg—0/6 (0%)2/6 (33.3%)
Crizotinib 250 mg—0/6 (0%)0/6 (0%)
Crizotinib 400 mg—0/6 (0%)1/6 (16.7%)
Most frequent other events
Most frequent other events
EventCrizotinib 150 mgCrizotinib 250 mgCrizotinib 400 mg
NauseaGastrointestinal disorders1/60/60/6
Alanine aminotransferase increasedInvestigations1/60/60/6
EpistaxisRespiratory, thoracic and mediastinal disorders0/60/61/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Crizotinib 150 mgCrizotinib 250 mgCrizotinib 400 mgTotal
<=18 years0000
Between 18 and 65 years66618
>=65 years0000
Sex: Female, Male
Sex: Female, Male(Participants)Crizotinib 150 mgCrizotinib 250 mgCrizotinib 400 mgTotal
Female0000
Male66618
08

Study locations

1 site
  • Pfizer Investigational Site
    Hachioji-shi, Tokyo, Japan
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2011, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2010
First posted
Dec 1, 2010
Start
Dec 2010
Primary completionActual
Jan 2011
CompletionActual
Jan 2011
Results first posted
Nov 29, 2011
Last update
Nov 29, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01250730
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 1, 2010
Start date
Dec 2010
Primary completion
Jan 2011
Completion
Jan 2011
Results posted
Nov 29, 2011
Last update
Nov 29, 2011

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Crizotinib

Start the discussion